Regulus Therapeutics reported revenue of $5.0 million for the third quarter of 2020, primarily from the completion of material transfers to Sanofi. The company achieved milestones from its collaboration with Sanofi, reducing outstanding debt to $4.7 million and extending the interest-only period through the end of 2021. The first patient was dosed in the Phase 1b clinical trial of RGLS4326 for ADPKD.